Deception, Pain, and Placebo: Applying the Brummett-Salter Deception Framework.

beneficence clinical ethics deception lying pain management placebo

Journal

The Hastings Center report
ISSN: 1552-146X
Titre abrégé: Hastings Cent Rep
Pays: United States
ID NLM: 0410447

Informations de publication

Date de publication:
Jan 2023
Historique:
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 3 3 2023
Statut: ppublish

Résumé

In this commentary, I explore the usefulness of the framework Abram Brummett and Erica K. Salter present in their article "Mapping the Moral Terrain of Clinical Deception." Deception cases are divisive because they nearly always evoke the metadilemma of clinical ethics: a clash between duties (in these cases, truth telling) and consequences (whatever good might come of the lie). Here, I describe a patient case in which the clinical team considered deceiving a patient about his pain-medicine dosage in exchange for his allowing the clinicians to properly care for his percutaneous endoscopic gastrostomy tube stoma, so as to prevent infection. Applying the framework that Brummett and Salter have developed helped our clinical team parse the numerous complex issues involved. The nuances of our case also illustrated additional ways in which the ethics of deception needs to be further refined.

Identifiants

pubmed: 36840336
doi: 10.1002/hast.1457
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-32

Informations de copyright

© 2023 The Hastings Center.

Références

A. Brummett and E. K. Salter, “Mapping the Moral Terrain of Clinical Deception,” Hastings Center Report 53, no. 1 (2023): 17-25.
Ibid.
J. A. Wasserman and M. C. Navin, “Capacity for Preferences: Respecting Patients with Compromised Decision-Making,” Hastings Center Report 48, no. 3 (2018): 31-39.
D. K. Sokol, “Can Deceiving Patients Be Morally Acceptable?,” BMJ 334 (2007): 984-86.; Brummett and Salter, “Mapping the Moral Terrain of Clinical Deception.”
Brummett and Salter, “Mapping the Moral Terrain of Clinical Deception,” 18.
Brummett and Salter, “Mapping the Moral Terrain of Clinical Deception”; Sokol, “Can Deceiving Patients Be Morally Acceptable?”
Sokol, “Can Deceiving Patients Be Morally Acceptable?”

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH